Cardlytics Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Der Umsatz von Cardlytics wird voraussichtlich um 8.9% pro Jahr zurückgehen, während der Jahresgewinn um 61.9% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 85.1% pro Jahr steigen.
Wichtige Informationen
61.9%
Wachstumsrate der Gewinne
85.14%
EPS-Wachstumsrate
| Media Gewinnwachstum | 18.4% |
| Wachstumsrate der Einnahmen | -8.9% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 07 Aug 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrative-Update • Sep 18
CDLX: Indemnification Settlement And Earnings Outlook Will Support Future Repricing Potential
Analysts have cut their Cardlytics fair value estimate from $15 to $10, citing updated assumptions that include a slightly higher discount rate, a smaller decline in expected revenue growth, a marginally lower profit margin outlook, and a reduced future P/E expectation. What’s in the News for Cardlytics Cardlytics settled an indemnification dispute with Amit Jain, founder and former chief executive and director of Bridg, related to the acquisition of Bridg in 2021, through a settlement and release agreement dated September 4, 2026.
Narrative-Update • Sep 04
CDLX: Lower Fair Value And Revenue Guidance Will Shape Balanced Return Outlook
Analysts have revised their price targets on Cardlytics, citing updated fair value estimates of $8 and a refreshed set of assumptions around discount rates, revenue trends, and future P/E expectations as the key drivers behind the change. What’s in the News for Cardlytics Cardlytics issued unaudited earnings guidance for the third quarter of 2026, with expected revenue in a range of US$34.0 million to US$39.0 million.
Narrative-Update • Aug 21
CDLX: Reverse Split And Margin Outlook Will Shape Future Repricing
Analysts have trimmed their fair value estimate for Cardlytics from $8.50 to $6.00. This reflects updated assumptions for weaker revenue growth, slightly lower profit margins, and a reduced future P/E multiple.Narrative-Update • Aug 06
CDLX: Reverse Split And Profitability Outlook Will Drive Future Repricing
Analysts have trimmed their Cardlytics fair value estimate from $10.75 to $8.50, pointing to updated assumptions for revenue trends, profitability, and future P/E that informed the latest price target cut reported in recent research. What’s in the News for Cardlytics Cardlytics received a Nasdaq notice on June 3, 2026, stating that its common stock had closed below the US$1.00 minimum bid price requirement for 30 consecutive business days, triggering a compliance period that runs until November 30, 2026.Narrative-Update • Jul 14
CDLX: Reverse Split And Margin Outlook Will Support A Higher Price
Analysts have trimmed their Cardlytics price targets by $0.25. They are factoring in a lower fair value estimate, a slightly higher discount rate, and expectations for weaker revenue growth, despite modestly stronger profit margins and a lower future P/E assumption.Narrative-Update • Jun 30
CDLX: Reverse Split And Nasdaq Compliance Efforts Will Drive Future Repricing Potential
Analysts have reduced their Cardlytics price target from $15.00 to $1.50, citing updated assumptions of slightly weaker revenue growth and profit margins, along with a modestly higher future P/E multiple. What’s in the News for Cardlytics On June 3, 2026, Cardlytics received a notice from Nasdaq that its common stock had closed below US$1.00 per share for 30 consecutive business days, triggering a deficiency under Nasdaq Listing Rule 5550(a)(2).Narrative-Update • Jun 16
CDLX: Reverse Split And Margin Outlook Will Drive Future Repricing
Analysts have raised their fair value estimate for Cardlytics to $10.75 from $1.08, citing updated price target work that incorporates unchanged discount rate assumptions, a slightly higher long term profit margin outlook, and a modestly lower future P/E multiple. What’s in the News for Cardlytics Cardlytics plans a 1 for 10 reverse stock split of its common stock, with the company’s shares expected to begin trading on a split adjusted basis on The Nasdaq Global Market on June 8, 2026, and the new CUSIP number set as 14161W303.Narrative-Update • Jun 02
CDLX: Reset Expectations And Partner Exit Will Drive Future Repricing
Analysts have edged Cardlytics' fair value estimate up to about $1.08 per share, while tightening assumptions around discount rate, revenue contraction, profit margins and future P/E. This reflects recent price target cuts to $1 to $1.25 that they see as better aligned with updated guidance and the impact of the BofA exit and Bridg sale.Narrative-Update • May 15
CDLX: Reset Guidance And Banking Shifts Will Drive Future Repricing Potential
Narrative update on Cardlytics The analyst price target for Cardlytics has shifted from $1.25 to $1.50, with analysts pointing to updated assumptions around discount rates, revenue trends, margins, and future P/E after recent resets in expectations following Q4 results, Q1 guidance, and the impact of the BofA exit and Bridg divestiture. Analyst Commentary Recent research has centered on how Cardlytics should be valued after its Q4 results, Q1 guidance, and the announced BofA exit and Bridg divestiture.Analyseartikel • May 11
Cardlytics, Inc. (NASDAQ:CDLX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Cardlytics, Inc. ( NASDAQ:CDLX ) just released its latest first-quarter results and things are looking bullish...Narrative-Update • May 01
CDLX: Reset Expectations And Banking Partner Shifts Will Drive Future Repricing
Analysts have nudged Cardlytics' average price target lower to about $1, with cuts from $2 to $1 and from $1.50 to $1.25. These changes reflect updated views after Q4 results, Q1 guidance, and the expected impact of the BofA exit and Bridg divestiture.Narrative-Update • Apr 17
CDLX: Reset Guidance And BofA Exit Will Drive Upside Potential
Narrative Update on Cardlytics Analysts have cut their Cardlytics price targets to a range of about $1 to $1.25, citing Q1 guidance that resets expectations following the Bank of America exit and Bridg divestiture and leaves the stock in what they describe as "show me" territory. Analyst Commentary Recent research updates underline that Q1 guidance and the effects of the Bank of America exit and Bridg divestiture are central to how analysts are framing Cardlytics today.Narrative-Update • Apr 03
CDLX: Reset Expectations And Partner Changes Will Shape Future Repricing
Analysts have trimmed Cardlytics' implied fair value from about $1.29 to roughly $1.04. This reflects recent price target cuts to $1 and $1.25 as they factor in softer revenue expectations and the impact of the BofA exit and Bridg divestiture.Narrative-Update • Mar 20
CDLX: Reset Guidance And One Bank Exit Will Define Upside Potential
Narrative update on Cardlytics Analysts have trimmed Cardlytics' implied fair value from about $2.00 to roughly $1.25, reflecting lower price targets around $1.00 to $1.25 after Q1 guidance reset expectations for revenue trends, margins and future P/E as the business adjusts to the BofA exit and Bridg divestiture. Analyst Commentary Recent Street research has centered on recalibrated price targets around Q1 guidance and the operational impact of the BofA exit and Bridg divestiture.Narrative-Update • Mar 06
CDLX: Reset Expectations And CFO Return Will Support Future Rerating
Analysts have trimmed their Cardlytics price target from $1.50 to $1.25, reflecting updated assumptions around fair value, revenue trends, and profitability following recent guidance resets and business changes. Analyst Commentary Recent commentary around the reduced US$1.25 price target centers on how quickly Cardlytics can adjust to its updated outlook and business mix after the Q1 guidance reset, the BofA exit, and the Bridg divestiture.Analyseartikel • Jan 08
Cardlytics, Inc. (NASDAQ:CDLX) Stock Catapults 30% Though Its Price And Business Still Lag The Industry
Those holding Cardlytics, Inc. ( NASDAQ:CDLX ) shares would be relieved that the share price has rebounded 30% in the...Seeking Alpha • Oct 06
Cardlytics: Debt Overhang Casts Shadow On Upside
Summary Cardlytics is dealing with a significant headwind in Q3 due to restrictions from its largest bank partner. CDLX sold off sharply following Q2 results, but has since rallied following a bullish report from Citron Research. Management is targeting positive FCF through growth with its newest large bank partner while also substantially lowering operating expenses. Debt remains the biggest risk, though the earliest maturity is not until April 2028. I remain cautious until I see evidence of sequential growth and improving cash burn. Read the full article on Seeking AlphaNarrative-Update • Aug 08
Bank Partnerships And Data-Driven Marketing Will Shape Future Markets
The notable downward revision in Cardlytics’ price target reflects sharply reduced revenue growth forecasts and a higher discount rate, resulting in a new consensus fair value of $2.10. What's in the News Cardlytics provided Q3 2025 revenue guidance of $52.2 million to $58.2 million.Analyseartikel • Jul 23
Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX) As Its Stock Soars 64%
Cardlytics, Inc. ( NASDAQ:CDLX ) shares have continued their recent momentum with a 64% gain in the last month alone...Analyseartikel • Jul 05
Is Cardlytics (NASDAQ:CDLX) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • May 29
Cardlytics, Inc. (NASDAQ:CDLX) Soars 30% But It's A Story Of Risk Vs Reward
Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...Analyseartikel • Apr 07
Why Investors Shouldn't Be Surprised By Cardlytics, Inc.'s (NASDAQ:CDLX) 30% Share Price Plunge
Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 30% in the last thirty...
Neues Narrative • Apr 03
US Neobank And Taiwan Office Will Unlock New Markets
Expansion into new sectors and partnerships with financial institutions and neobanks is expected to diversify the customer base and boost revenue.Analyseartikel • Mar 11
Cardlytics (NASDAQ:CDLX) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Feb 21
Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX)
It's not a stretch to say that Cardlytics, Inc.'s ( NASDAQ:CDLX ) price-to-sales (or "P/S") ratio of 0.5x right now...Seeking Alpha • Feb 13
Cardlytics: Short-Term Headwinds Drive Long-Term Success
Summary Cardlytics, Inc. offers an asymmetric investment opportunity for those who can handle stock price volatility and slow business progress. Recent issues with ad deliveries have impacted revenue and market sentiment but positioned the company for long-term success. The shift to engagement-based pricing is expected to drive broader platform adoption. Trading at just 0.51x P/S and 1.10x EV/Revenue, Cardlytics presents significant upside potential from current valuations. Amex Partnership could add $600 million in market value based on $35 million in incremental EBITDA for 2025. Read the full article on Seeking AlphaAnalyseartikel • Jan 10
At US$3.35, Is It Time To Put Cardlytics, Inc. (NASDAQ:CDLX) On Your Watch List?
Cardlytics, Inc. ( NASDAQ:CDLX ), might not be a large cap stock, but it saw significant share price movement during...Seeking Alpha • Dec 07
Cardlytics Continues Revenue Contraction Amid Worsening Economics
Summary Cardlytics, Inc. beat revenue and earnings estimates, but faces declining unit economics and revenue stabilization challenges. The AdTech market is projected to grow significantly, yet CDLX struggles with delivery inefficiencies, declining ARPU, and advertiser hesitancy, impacting its financial performance. Recent financial trends show falling revenue, negative operating income, and high stock-based compensation, with significant cash burn and a 52.1% stock price decline over the past year. Management's turnaround efforts may take several quarters, with increased R&D spending expected to further negatively affect operating results. My outlook on CDLX is to sell. Read the full article on Seeking AlphaAnalyseartikel • Nov 23
Estimating The Intrinsic Value Of Cardlytics, Inc. (NASDAQ:CDLX)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Cardlytics fair value estimate is US$3.50 Current share price...Analyseartikel • Nov 05
After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar
Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Analyseartikel • Oct 15
Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Sep 17
Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)
Summary Shares have fallen nearly 50% since the Q2 earnings report, which came in well below management’s guidance. With Q3 guidance pointing to further weakness, the company’s financial health hinges on management’s execution towards solving the ongoing issues on its ads platform. Assuming no additional setbacks, the company should return to growth next year and generate positive FCF. While risks remain high, the current valuation is undemanding, leading me to maintain a Neutral rating. Read the full article on Seeking AlphaAnalyseartikel • Aug 09
Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk
Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders that were waiting for something to happen have been dealt a blow with a...Seeking Alpha • Jul 02
Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain
Summary Cardlytics shares have declined significantly after Q1 earnings came in below management’s guidance. Key metrics show that the business is performing well. Recent steps taken by management have extended its debt until 2029, leaving the company in a more stable financial position. CDLX has multiple growth levers and significant risks that investors should consider. Read the full article on Seeking AlphaAnalyseartikel • May 31
Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
The Cardlytics, Inc. ( NASDAQ:CDLX ) share price has softened a substantial 30% over the previous 30 days, handing back...Seeking Alpha • Apr 17
The Power Of Cardlytics' Data Partnerships Including Bank of America
Summary Cardlytics recently appointed Liane Hornsey to its Board of Directors, which could attract new investors and accelerate hiring and productivity. The company offers a suite of solutions for advertising, marketing, and customer engagement through its own mobile application and partnerships with financial institutions. Future growth projects, synergies, database integration, and new partnerships have the potential to drive net sales growth and increase investor attention. Read the full article on Seeking AlphaAnalyseartikel • Apr 10
Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors
Despite an already strong run, Cardlytics, Inc. ( NASDAQ:CDLX ) shares have been powering on, with a gain of 81% in the...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2027 | 161 | -41 | -8 | 10 | 4 |
| 12/31/2026 | 149 | -39 | -8 | 6 | 4 |
| 6/30/2026 | 190 | -110 | -11 | 1 | N/A |
| 3/31/2026 | 211 | -107 | -4 | 10 | N/A |
| 12/31/2025 | 233 | -103 | -6 | 9 | N/A |
| 9/30/2025 | 241 | -105 | -18 | -1 | N/A |
| 6/30/2025 | 256 | -177 | -20 | -1 | N/A |
| 3/31/2025 | 267 | -175 | -17 | 2 | N/A |
| 12/31/2024 | 278 | -189 | -28 | -9 | N/A |
| 9/30/2024 | 293 | -275 | -27 | -9 | N/A |
| 6/30/2024 | 305 | -153 | -26 | -9 | N/A |
| 3/31/2024 | 312 | -173 | -22 | -8 | N/A |
| 12/31/2023 | 309 | -135 | -13 | 0 | N/A |
| 9/30/2023 | 303 | -412 | -28 | -16 | N/A |
| 6/30/2023 | 296 | -382 | -44 | -32 | N/A |
| 3/31/2023 | 295 | -485 | -58 | -44 | N/A |
| 12/31/2022 | 299 | -465 | -67 | -54 | N/A |
| 9/30/2022 | 306 | -99 | -55 | -41 | N/A |
| 6/30/2022 | 298 | -150 | -51 | -37 | N/A |
| 3/31/2022 | 282 | -71 | -58 | -46 | N/A |
| 12/31/2021 | 267 | -129 | -51 | -39 | N/A |
| 9/30/2021 | 244 | -124 | -45 | -32 | N/A |
| 6/30/2021 | 225 | -94 | -40 | -27 | N/A |
| 3/31/2021 | 195 | -67 | -29 | -17 | N/A |
| 12/31/2020 | 187 | -55 | -18 | -8 | N/A |
| 9/30/2020 | 189 | -45 | -20 | -9 | N/A |
| 6/30/2020 | 199 | -38 | -2 | 7 | N/A |
| 3/31/2020 | 220 | -24 | N/A | 10 | N/A |
| 12/31/2019 | 210 | -17 | N/A | 11 | N/A |
| 9/30/2019 | 189 | -32 | N/A | 3 | N/A |
| 6/30/2019 | 167 | -33 | N/A | -9 | N/A |
| 3/31/2019 | 154 | -39 | N/A | -20 | N/A |
| 12/31/2018 | 151 | -53 | N/A | -19 | N/A |
| 9/30/2018 | 142 | -46 | N/A | -20 | N/A |
| 6/30/2018 | 139 | -41 | N/A | -29 | N/A |
| 3/31/2018 | 136 | -33 | N/A | -16 | N/A |
| 12/31/2017 | 130 | -25 | N/A | -22 | N/A |
| 9/30/2017 | 128 | -28 | N/A | -19 | N/A |
| 6/30/2017 | 127 | -51 | N/A | -16 | N/A |
| 3/31/2017 | 120 | -77 | N/A | -26 | N/A |
| 12/31/2016 | 113 | -77 | N/A | -32 | N/A |
| 12/31/2015 | 78 | -42 | N/A | -29 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CDLX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: CDLX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: CDLX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: CDLXDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-8.9% pro Jahr).
Hohe Wachstumseinnahmen: CDLXDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-8.9% pro Jahr).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CDLX in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/21 15:09 |
| Aktienkurs zum Tagesende | 2026/09/21 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Cardlytics, Inc. wird von 11 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Omar Dessouky | BofA Global Research |
| Jason Kreyer | Craig-Hallum Capital Group LLC |
| Robert Coolbrith | Evercore ISI |